Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
14.5M
-
Number of holders
-
101
-
Total 13F shares, excl. options
-
10.5M
-
Shares change
-
+60.9K
-
Total reported value, excl. options
-
$354M
-
Value change
-
+$6.76M
-
Put/Call ratio
-
2.54
-
Number of buys
-
46
-
Number of sells
-
-46
-
Price
-
$33.68
Significant Holders of Inhibrx Biosciences, Inc. - Common Stock (INBX) as of Q3 2025
116 filings reported holding INBX - Inhibrx Biosciences, Inc. - Common Stock as of Q3 2025.
Inhibrx Biosciences, Inc. - Common Stock (INBX) has 101 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10.5M shares
of 14.5M outstanding shares and own 72.52% of the company stock.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (1.79M shares), PERCEPTIVE ADVISORS LLC (1.33M shares), Sanofi (1.16M shares), HighTower Advisors, LLC (872K shares), BlackRock, Inc. (685K shares), VANGUARD GROUP INC (595K shares), MORGAN STANLEY (443K shares), Sofinnova Investments, Inc. (440K shares), Woodline Partners LP (337K shares), and MILLENNIUM MANAGEMENT LLC (298K shares).
This table shows the top 101 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.